Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy
Background Current treatment options for stage III non-small cell lung cancer (NSCLC) consist of different combinations of chemotherapy, surgery, radiotherapy and immunotherapy. Treatment choices are highly individual decisions, in which adverse events (AEs) are relevant for decision-making. This st...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2020-09-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/6/3/00010-2020.full |